novo nordisk glp-1 products promotes new receptor agonist to fight diabetes, obesity < Pharma < Article Blockbuster GLP-1 Diabetes and Weight

Our oral-versus-injection BPC-157 comparison discusses the formulation question in more detail

Hair loss or alopecia is not reported as a side effect in the Ozempic (semaglutide) injection studies in the prescribing information, but has been reported by some people using the medicine

In seven large cardiovascular studies, all agents shown at least non-inferiority, with liraglutide, subcutaneous semaglutide, and dulaglutide revealing statistically significant decreases in cardiovascular outcomes (Sheahan et al

It is important to note that the FDA-approved clinical trials for semaglutide and tirzepatide studied the injectable formulations

This is why the 3-month cycle framework exists and why a single injection produces minimal results compared to a structured protocol